REVERSE IMMUNIZATION Trademark

Trademark Overview


On Thursday, July 8, 2021, a trademark application was filed for REVERSE IMMUNIZATION with the United States Patent and Trademark Office. The USPTO has given the REVERSE IMMUNIZATION trademark a serial number of 90818040. The federal status of this trademark filing is REGISTERED as of Tuesday, January 30, 2024. This trademark is owned by CANOPY IMMUNO-THERAPEUTICS LTD.. The REVERSE IMMUNIZATION trademark is filed in the Pharmaceutical Products category with the following description:

Proteins being recombinant proteins in the nature of pharmaceutical preparations and substances for the treatment of autoimmune, allergic and inflammatory diseases and disorders; Proteins being recombinant proteins in the nature of pharmaceutical preparations and substances for the treatment of autoimmune, allergic and inflammatory diseases by eliminating specific lymphocytes lineages or modulating the immune response using a variety of recombinant proteins; Pharmaceutical preparations and substances for the treatment of autoimmune, allergic and inflammatory diseases and disorders by modulating the immune system by recombinant proteins that contain a targeting moiety and an effector moiety to eliminate specific lymphocytes lineages and attenuate or block the antibody creation and antigen specific immune response in autoimmune, Allergic and inflammatory diseases; Pharmaceutical preparations and substances for the treatment of autoimmune, allergic and inflammatory diseases and disorders ...
reverse immunization

General Information


Serial Number90818040
Word MarkREVERSE IMMUNIZATION
Filing DateThursday, July 8, 2021
Status700 - REGISTERED
Status DateTuesday, January 30, 2024
Registration Number7295729
Registration DateTuesday, January 30, 2024
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements


Goods and ServicesProteins being recombinant proteins in the nature of pharmaceutical preparations and substances for the treatment of autoimmune, allergic and inflammatory diseases and disorders; Proteins being recombinant proteins in the nature of pharmaceutical preparations and substances for the treatment of autoimmune, allergic and inflammatory diseases by eliminating specific lymphocytes lineages or modulating the immune response using a variety of recombinant proteins; Pharmaceutical preparations and substances for the treatment of autoimmune, allergic and inflammatory diseases and disorders by modulating the immune system by recombinant proteins that contain a targeting moiety and an effector moiety to eliminate specific lymphocytes lineages and attenuate or block the antibody creation and antigen specific immune response in autoimmune, Allergic and inflammatory diseases; Pharmaceutical preparations and substances for the treatment of autoimmune, allergic and inflammatory diseases and disorders by modulating the immune system by recombinant proteins that contain a targeting moiety and an effector moiety to eliminate specific lymphocytes lineages and attenuate or block the creation of the antibodies IgG, IgE or IgA and antigen specific immune response in autoimmune, allergic and inflammatory diseases; Proteins including recombinant proteins pharmaceutical preparations and substances with potential immunomodulation activity to treat under and over responsiveness of the immune system

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateWednesday, September 15, 2021
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameCANOPY IMMUNO-THERAPEUTICS LTD.
Party Type30 - Original Registrant
Legal Entity Type99 - Other
AddressMagadim 3087500
IL

Party NameCANOPY IMMUNO-THERAPEUTICS LTD.
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressMagadim 3087500
IL

Trademark Events


Event DateEvent Description
Tuesday, January 30, 2024NOTICE OF REGISTRATION CONFIRMATION EMAILED
Tuesday, January 30, 2024REGISTERED-SUPPLEMENTAL REGISTER
Thursday, December 28, 2023ELECTRONIC RECORD REVIEW COMPLETE
Friday, December 22, 2023ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED
Monday, July 3, 2023APPROVED FOR REGISTRATION SUPPLEMENTAL REGISTER
Thursday, May 25, 2023TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, May 25, 2023CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, May 25, 2023TEAS REQUEST FOR RECONSIDERATION RECEIVED
Tuesday, May 23, 2023APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Tuesday, May 23, 2023TEAS CHANGE OF CORRESPONDENCE RECEIVED
Tuesday, May 23, 2023TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Tuesday, May 23, 2023TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Tuesday, May 23, 2023ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Tuesday, May 23, 2023TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Tuesday, May 23, 2023TEAS CHANGE OF OWNER ADDRESS RECEIVED
Sunday, May 14, 2023APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Sunday, May 14, 2023APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Wednesday, February 15, 2023NOTIFICATION OF FINAL REFUSAL EMAILED
Wednesday, February 15, 2023FINAL REFUSAL E-MAILED
Wednesday, February 15, 2023FINAL REFUSAL WRITTEN
Tuesday, November 15, 2022TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, November 15, 2022CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, November 10, 2022ASSIGNED TO LIE
Wednesday, September 28, 2022TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, April 6, 2022NOTIFICATION OF NON-FINAL ACTION E-MAILED
Wednesday, April 6, 2022NON-FINAL ACTION E-MAILED
Wednesday, April 6, 2022NON-FINAL ACTION WRITTEN
Monday, March 28, 2022ASSIGNED TO EXAMINER
Wednesday, September 15, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Monday, July 12, 2021NEW APPLICATION ENTERED